Ramipril

Generic Name: Ramipril

Brand Names: Altace, Altace HCT

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₂N_₂O_₅

CAS Number: 87333-19-5

Unique Ingredient Identifier: L35JN3I7SJ

Background: Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Indication: For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event

Associated Therapies: -

Clinical Trials

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-01-25

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1354

Registration Number: NCT00281593

Locations: 🇺🇸
1236.1.573 Boehringer Ingelheim Investigational Site, Long Beach, California, United States
🇺🇸
1236.1.560 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
🇺🇸
1236.1.523 Boehringer Ingelheim Investigational Site, Buena Park, California, United States

and more 116 locations

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2023-12-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 812

Registration Number: NCT00274599

Locations: 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Harold B. Betton, M.D., Little Rock, Arkansas, United States
🇺🇸
GFI Pharmaceuticals, Evansville, Indiana, United States

and more 7 locations

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 801

Registration Number: NCT00274612

Locations: 🇦🇹
Rehabilitationszentrum für Herz- und Kreislauferkrankungen, Bad Tatzmannsdorf, Austria
🇦🇹
Landeskrankenhaus Graz West, Graz, Austria
🇦🇹
Univ.-Klinik für Innere Medizin III, Wien, Austria

and more 16 locations

Ramipril in Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2006-01-09

Last Posted Date: 2008-07-22

Lead Sponsor: University of Zurich

Target Recruit Count: 13

Registration Number: NCT00273533

FOCUS:Focus On Coronary Unstable Syndromes

Phase 3

Completed

Conditions: Myocardial Ischemia

First Posted Date: 2005-12-22

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Registration Number: NCT00268619

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT00240422

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Nürnberg, Germany
🇩🇪
Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪
Universität Erlangen-Nürnberg, Nürnberg, Germany

and more 1 locations

Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Phase 3

Terminated

Conditions: Hypertension
Type 2 Diabetes
Albuminuria

First Posted Date: 2005-09-21

Last Posted Date: 2007-11-08

Lead Sponsor: Institut de Recherches Cliniques de Montreal

Target Recruit Count: 50

Registration Number: NCT00208221

Locations: 🇨🇦
Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Phase 4

Completed

Conditions: Peripheral Arterial Disease

First Posted Date: 2005-09-15

Last Posted Date: 2009-01-29

Lead Sponsor: Baker Heart Research Institute

Target Recruit Count: 40

Registration Number: NCT00168467

Locations: 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Phase 4

Completed

Conditions: Cardiovascular Diseases

First Posted Date: 2005-09-12

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31546

Registration Number: NCT00153101

Locations: 🇺🇸
502.373.0247 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸
502.373.0177 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States
🇦🇺
502.373.0529 Launceston General Hospital, Launceston, Tasmania, Australia

and more 729 locations

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Ramipril
Drug: Spironolactone

First Posted Date: 2005-09-01

Last Posted Date: 2013-03-22

Lead Sponsor: Vanderbilt University

Target Recruit Count: 455

Registration Number: NCT00141778

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy